AVEO Pharmaceuticals — Investor Presentation (April 2017)
32 slides from AVEO Pharmaceuticals's investor presentation, Apr 5, 2017
Slide 1: AVEO Overview April 2017
AVEO Overview April 2017 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
Slide 3: Multiple Opportunities for Potential Value Creation
TIVO-1 (1st Line RCC) * Ocular SCCHN / AML (Investigator) Esophageal Cancer Cachexia TIVO-3 (U.S. Phase 3 Registration Study in RCC) TiNivo (+Opdivo® RCC) PAH Multiple Opportunities for Potential Value Creation *Filed in EU by EUSA FEB 2016 EUSA received 180 day outstanding issues JAN 2017 Seeking P
Slide 4: Tivozanib Potential Milestone Timeline in RCC
Tivozanib Potential Milestone Timeline in RCC MAA Review TIVO-3 : Tivo v. Sorafenib US Regulatory Decision EU Regulatory Decision NDA Review 2016 2017 2018 2019 2020 Ph 2 Expansion Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1Q 2018 Ph 1 Data Estimated 1H 2017 Ph 1 Tivo + Opdivo® Potent
Slide 5: Large and Growing RCC Opportunity
Large and Growing RCC Opportunity ~$1.7 Billion* ~$1.4 Billion* * Total RCC market includes all stages of disease and treatment options. Source: GlobalData Forecast 2023 Market opportunity expected to grow to >$3 billion in Europe and North America* Market needs: Improved tolerability in first line
Slide 6: Tivozanib AVEO's North American Registration Strategy
Tivozanib AVEO’s North American Registration Strategy
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 8: TIVO-1: Unsurpassed PFS in 1st Line RCC
TIVO-1: Unsurpassed PFS in 1st Line RCC in Phase 3 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability pr
Slide 9: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and
Slide 10: Tivozanib is Well Tolerated, Potential Preferred TKI for PD-1 Combination
Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD-1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta5 (n=189) Nexavar3 (n=257) Lenvima4 (n=52) Cometriq2 (n=331) Tivozanib3 (n=259) Hypertension 30% (15%) 40% (4%)
Slide 11: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC Incidence (%) Incidence (%) Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Dose Reductions Dose Interruptions Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Cabozantinib5 Lenvatinib+Everolimus6 1. Motzer et.al. J
Slide 12: Tivozanib Uniquely Positioned in 1st Line RCC
? 1 Motzer, et. al. ESMO 2012 (COMPARZ): 1st Line study, sutent vs. votrient. 2 Hutson, et. al. Lancet Oncol 2013; 14: 1245; 1st line Phase 3 study vs sorafenib. 3 Motzer, et. al. JCO Oct 2013; 1st Line TIVO-1 Phase 3 study, tivozanib vs. sorafenib. 4 Choueri, et. al. ESMO 2016. Poor and Intermediat
Slide 13: TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC
TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT Designed to
Slide 14: Tivozanib Efficacy in VEGF TKI Refractory Setting
Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^cabozantinib USPI 1. Motzer et al Lancet Oncol 2013; 14: 552–62 2. Motzer et al Lancet Oncol 2014 3. Hutson et al ASCO 2015 4.
Slide 15: Tivozanib European Registration Strategy
Tivozanib European Registration Strategy
Slide 16: EUSA Pharma Oncology Licensing Agreement
EUSA Pharma Oncology Licensing Agreement Specialty pharmaceutical company with commercial operations in the US and Europe, distribution network in 40 countries Spinout of Jazz Pharmaceuticals (March 2015) EU filing February 2016, received day 180 List of Outstanding Issues January 2017 LOI signifies
Slide 17: Support for Tivozanib MAA Filing for RCC
Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study
Slide 18: Tivozanib PD-1 Combination Setting
Tivozanib PD-1 Combination Setting
Slide 19: Rationale for Combining VEGF + PD-(L)1 Inhibitors
Rationale for Combining VEGF + PD-(L)1 Inhibitors Gunturi, McDermott Current Treatment Options in Oncology 2014 Plimack International Kidney Cancer Symposium 2014
Slide 20: Tivozanib has Immunomodulatory Properties
Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD-1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034
Slide 21: Early Data for the Combination of PD-1 + VEGF TKIs
Early Data for the Combination of PD-1 +VEGF TKIs: Demonstrated Promising Responses with Challenging Toxicity 1 Atkins et. al., ESMO 2016 2 Larkin et. al., ESMO 2016 Phase Ib dose-finding studies of axitinib plus pembrolizumab or avelumab in treatment-naïve patients with advanced renal cell carcinom
Slide 22: Sunitinib & Pazopanib Have Overlapping Toxicities with PD-1s
Sunitinib & Pazopanib, the most widely used VEGF TKIs, have potentially prohibitive overlapping toxicities with PD-1s Courtesy of Dr. S. Pal, ASCO GU 2015
Slide 23: Significant TKI Dose Reductions Recommended to Combine with PD1s
Significant reductions of TKI dose to manage AEs have been recommended to safely combine some TKIs with PD1s in RCC CaboNivo1: Cabo recommended dose reduction from 60 to 40mg Lenvatinib + Pembro2: Lenv recommended dose reduction 24 to 20mg Reduced Dose May Adversely Impact Efficacy 1 Apolo et. al.,
Slide 24: Phase 1/2 TiNivo Study
Phase 1 TiNivo Study Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks N = 6 - 12 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks Further evaluate the antineoplastic activity and safety Phase 1* Phase 2 Maximum tolerated dose N =
Slide 25: High Potential Value Pipeline Programs
High Potential Value Pipeline Programs
Slide 26: Advancing Robust Pipeline Through Partnership
Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *Subject to milestone payment & royalty payment obligations to SVH AV-380 (GDF-15 inhibitor MAb) Indication: cachexia Incidence: 5M+ in US alone
Slide 27: AV-353: 1st-in-class Opportunity in Pulmonary Arterial Hypertension
AV-353: 1st-in-class opportunity to address major unmet need in pulmonary arterial hypertension (PAH) as potential to be first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sale
Slide 28: Financials and Portfolio Summary
Financials and Portfolio Summary
Slide 29: Financial Highlights
Financial Highlights Cash on hand would fund planned operations into 2Q 2018*; beyond TIVO-3 readout which is expected 1Q 2018. $23.3M in cash and investments as of 4Q 2016 $15.5M in net proceeds from March 2017 public offering $0.5M milestone payment received from CANbridge March 2017 Potential acc
Slide 30: Potential Corporate Milestones
Potential Corporate Milestones 2017 2018 Regulatory decision in EU (1H17) TIVO-3 PFS data/OS trend (1Q18) Development milestones for AV-380 Manufacturing transfer (2107) and re-initiation of AV-203 clinical dev. (2018) Phase 1 data (1H17) TIVO-3 enrollment completion (June 2017) Pre-planned futility
Slide 31: AVEO Oncology Highlights
AVEO Oncology Highlights Retained significant North American rights for all oncology therapeutic assets Executing on development strategies for tivozanib Enrolling Ph 3 refractory RCC study (TIVO-3) to support 1st & 3rd line indications Enrolling Ph 1/2 tivozanib + Opdivo® combination study (TiNivo)
Slide 32: AVEO Overview April 2017
AVEO Overview April 2017
AVEO Pharmaceuticals — Investor Presentation (April 2017) on 6ix